Eisai Starts Domestic Study For Farletuzumab For Ovarian Cancer
This article was originally published in PharmAsia News
Executive Summary
Eisai started a Japanese domestic clinical study for farletuzumab on patients with ovarian cancer. The drug is developed by Eisai U.S. subsidiary Morphotek, which Eisai acquired in 2007. Farletuzumab is an anti-folate receptor alpha mAb undergoing Phase III trials in the U.S. and Europe for ovarian cancer. Eisai is planning a cross-regional study aiming to submit new drug applications in Japan and China as early as 2012.This is the second international clinical study for the company, which has also conducted a simultaneous study in Japan, the U.S. and Europe for severe sepsis drug eritoran. (Click here for more - Japanese language)"Eisai To Develop Domestic Antibody Drug For Ovarian Cancer" - Chemical Daily (8/25/2010)